National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Mepolizumab (Nucala®) is indicated as an add-on treatment for severe refractory eosinophilic asthma in adult patients.

Rapid Review

Commenced Completed Outcome
16/03/2016 04/04/2016 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
29/07/2016  01/03/2017 Reimbursement Not Recommended at the Submitted Price.



The HSE has approved reimbursement following confidential price negotiations; May 2018